Norihito Uemura1,2, Jun Ueda1, Toru Yoshihara3, Masashi Ikuno1, Maiko T Uemura1,2, Hodaka Yamakado1, Masahide Asano3, John Q Trojanowski2, Ryosuke Takahashi1. 1. Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan. 2. Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 3. Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Abstract
BACKGROUND: Patients with Parkinson's disease (PD) show motor symptoms as well as various non-motor symptoms. Postmortem studies of PD have suggested that initial alpha-synuclein (α-Syn) pathology develops independently in the olfactory bulb and lower brainstem, spreading from there stereotypically. However, it remains unclear how these two pathological pathways contribute to the clinicopathological progression of PD. OBJECTIVE: The objective of this study was to examine the clinicopathological contribution of α-Syn spread from the olfactory bulb. METHODS: We conducted pathological and behavioral analyses of human α-Syn bacterial artificial chromosome transgenic mice injected with α-Syn preformed fibrils into the bilateral olfactory bulb up to 10 months postinjection. RESULTS: α-Syn preformed fibril injections induced more widespread α-Syn pathology in the transgenic mice than that in wild-type mice. Severe α-Syn pathology in the transgenic mice injected with α-Syn preformed fibrils was initially observed along the olfactory pathway and later in the brain regions that are included in the limbic system and have connections with it. The α-Syn pathology was accompanied by regional atrophy, neuron loss, reactive astrogliosis, and microglial activation, which were remarkable in the hippocampus. Behavioral analyses revealed hyposmia, followed by anxiety-like behavior and memory impairment, but not motor dysfunction, depression-like behavior, or circadian rhythm disturbance. CONCLUSION: Our data suggest that α-Syn spread from the olfactory bulb mainly affects the olfactory pathway and limbic system as well as its related regions, leading to the development of hyposmia, anxiety, and memory loss in PD.
BACKGROUND: Patients with Parkinson's disease (PD) show motor symptoms as well as various non-motor symptoms. Postmortem studies of PD have suggested that initial alpha-synuclein (α-Syn) pathology develops independently in the olfactory bulb and lower brainstem, spreading from there stereotypically. However, it remains unclear how these two pathological pathways contribute to the clinicopathological progression of PD. OBJECTIVE: The objective of this study was to examine the clinicopathological contribution of α-Syn spread from the olfactory bulb. METHODS: We conducted pathological and behavioral analyses of human α-Syn bacterial artificial chromosome transgenic mice injected with α-Syn preformed fibrils into the bilateral olfactory bulb up to 10 months postinjection. RESULTS: α-Syn preformed fibril injections induced more widespread α-Syn pathology in the transgenic mice than that in wild-type mice. Severe α-Syn pathology in the transgenic mice injected with α-Syn preformed fibrils was initially observed along the olfactory pathway and later in the brain regions that are included in the limbic system and have connections with it. The α-Syn pathology was accompanied by regional atrophy, neuron loss, reactive astrogliosis, and microglial activation, which were remarkable in the hippocampus. Behavioral analyses revealed hyposmia, followed by anxiety-like behavior and memory impairment, but not motor dysfunction, depression-like behavior, or circadian rhythm disturbance. CONCLUSION: Our data suggest that α-Syn spread from the olfactory bulb mainly affects the olfactory pathway and limbic system as well as its related regions, leading to the development of hyposmia, anxiety, and memory loss in PD.
Authors: G Webster Ross; Robert D Abbott; Helen Petrovitch; Caroline M Tanner; Daron G Davis; James Nelson; William R Markesbery; John Hardman; Kamal Masaki; Lenore Launer; Lon R White Journal: Mov Disord Date: 2006-12 Impact factor: 10.338
Authors: Michelle E Fullard; Baochan Tran; Lama M Chahine; James F Morley; Sharon X Xie; Jon B Toledo; Christi Scordia; Carly Linder; Rachael Purri; Daniel Weintraub; John E Duda Journal: Parkinsonism Relat Disord Date: 2016-02-19 Impact factor: 4.891
Authors: Daniel Weintraub; Andrew B Newberg; Mark S Cary; Andrew D Siderowf; Paul J Moberg; Galit Kleiner-Fisman; John E Duda; Matthew B Stern; David Mozley; Ira R Katz Journal: J Nucl Med Date: 2005-02 Impact factor: 10.057
Authors: Norihito Uemura; Maiko T Uemura; Kelvin C Luk; Virginia M-Y Lee; John Q Trojanowski Journal: Trends Mol Med Date: 2020-05-01 Impact factor: 11.951
Authors: Daniel M Mason; Negin Nouraei; Deepti B Pant; Kristin M Miner; Daniel F Hutchison; Kelvin C Luk; John F Stolz; Rehana K Leak Journal: Mol Neurodegener Date: 2016-06-30 Impact factor: 14.195
Authors: Tarun N Bhatia; Rachel N Clark; Patrick G Needham; Kristin M Miner; Anuj S Jamenis; Elizabeth A Eckhoff; Nevil Abraham; Xiaoming Hu; Peter Wipf; Kelvin C Luk; Jeffrey L Brodsky; Rehana K Leak Journal: Neurotherapeutics Date: 2021-09-15 Impact factor: 6.088
Authors: Christopher Käufer; Cara S Schreiber; Anna-Sophia Hartke; Ivo Denden; Stephanie Stanelle-Bertram; Sebastian Beck; Nancy Mounogou Kouassi; Georg Beythien; Kathrin Becker; Tom Schreiner; Berfin Schaumburg; Andreas Beineke; Wolfgang Baumgärtner; Gülsah Gabriel; Franziska Richter Journal: EBioMedicine Date: 2022-04-16 Impact factor: 11.205